Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – SKOV3 tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Transduction, Control, Incubation, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Activity Assay, In Vivo, Expressing, Luciferase, In Vivo Imaging

Journal: bioRxiv

Article Title: Modular Albumin-Chaperoned NIR-II Nanofluorophores Enables Pan-Ovarian Cancer Imaging Across Multiscale Tumor Models

doi: 10.64898/2026.05.06.717945

Figure Lengend Snippet: (a) RNA sequencing data confirming the biomarker expression levels of FOLR1 and SPARC genes in SKOV3 and OVCAR8 tumor cells. (b) SKOV3 cell viability following BSA-FA@SP2 treatment [1-200µg/mL]. (c) IVIS fluorescence images of SKOV3 cultures after 24h treatment with DSPE-PEG@, BSA@, and BSA-FA@SP2 nanofluorophores, with (d) corresponding radiant intensities. (e) Schematic diagram showing experimental designs for time-dependent uptake studies. (f,h) IVIS fluorescence images of cellular uptake of BSA-FA@SP2 in (f) SKOV3 and (h) OVCAR8, with (g,i) corresponding radiant intensities. (j) Schematic diagram showing experimental designs for inhibition studies. (k, m) IVIS fluorescence images of cell uptake of BSA-FA@SP2 in (k) SKOV3 and (m) OVCAR8 following treatment with media (control: microcentrifuge tube 2), SPARC-blocking solution (10µM, microcentrifuge tube 3), and FOLR-blocking solution (10µM, microcentrifuge tube 4). microcentrifuge tube 1 serves as a cell media control, with (l,n) corresponding radiant intensities. All IVIS images were collected with λ ex : 675nm and λ em : 840nm.

Article Snippet: Tumor-On-Chip Cell Cluster Growth and Cell Viability: The human ovarian carcinoma cell line SKOV3 (ATCC) was maintained and expanded following standard culture protocols as previously described.

Techniques: RNA Sequencing, Biomarker Discovery, Expressing, Fluorescence, Inhibition, Control, Blocking Assay

Journal: bioRxiv

Article Title: Modular Albumin-Chaperoned NIR-II Nanofluorophores Enables Pan-Ovarian Cancer Imaging Across Multiscale Tumor Models

doi: 10.64898/2026.05.06.717945

Figure Lengend Snippet: (a) Schematic of the on-chip platform featuring a microfluidic channel mimicking leaky vasculature and a tumor cluster. (b) Representative bright-field (top) and live/dead fluorescence (bottom) images of SKOV3 cell clusters. (c) Live/dead assay fluorescence images of SKOV3 clusters following 36h perfusion of nanofluorophore treatments with (d) corresponding cell viability quantification using a MATLAB script (See Experimental Methods), n = 6. (e-g) IVIS images of SKOV3 clusters after 36h perfusion with (e) DSPE-PEG@SP2, (f) BSA@SP2, and (g) BSA-FA@SP2 with (h) respective radiant intensities, n = 6. All IVIS images were collected with λ ex : 675nm and λ em : 840nm.

Article Snippet: Tumor-On-Chip Cell Cluster Growth and Cell Viability: The human ovarian carcinoma cell line SKOV3 (ATCC) was maintained and expanded following standard culture protocols as previously described.

Techniques: Fluorescence, Live Dead Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Long non-coding RNA KCNQ1OT1 promotes ovarian cancer cell malignant characteristics by targeting the miR-140-5p/KLK10 axis

doi: 10.3892/etm.2026.13129

Figure Lengend Snippet: Expression of target genes in OC datasets and cell lines. Principal component analysis plots showing expression patterns in the (A) GSE66957 and (C) GSE47841 datasets. Volcano plots illustrating differentially expressed genes in the (B) GSE66957 and (D) GSE47841 datasets. Differential expression of (E) KCNQ1OT1 ( GSE66957 ), (F) KLK10 ( GSE66957 ) and (G) miR-140-5p ( GSE47841 ). (H) Relative expression levels of KCNQ1OT1, KLK10 and miR-140-5p in SKOV3 OC cells and IOSE80 normal ovarian epithelial cells. * P<0.05 and ** P<0.01. OC, ovarian cancer; KCNQ1OT1, potassium voltage-gated channel subfamily Q member 1 opposite strand/antisense transcript 1; KLK10, kallikrein-related peptidase 10; miR, microRNA; Dim, dimension; FC, fold change.

Article Snippet: IOSE80 (normal ovarian epithelial) and SKOV3 (OC) cell lines were sourced from Procell Life Science & Technology Co., Ltd. IOSE80 cells were maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) and SKOV3 cells in McCoy's 5A medium (Gibco; Thermo Fisher Scientific, Inc.), both supplemented with 10% FBS (HyClone; Cytiva) and 1% penicillin-streptomycin, at 37 ̊C in a 5% CO 2 humidified incubator.

Techniques: Expressing, Quantitative Proteomics

Journal: Cancers

Article Title: Comprehensive Pan-Cancer Analysis Identifies POFUT1 as a Prognostic Biomarker and Potential Therapeutic Target Associated with Immune Evasions

doi: 10.3390/cancers18091342

Figure Lengend Snippet: Protein network interaction and functional enrichment analysis of POFUT1. ( A ) STRING database-derived interaction network displaying the top 46 proteins with highest interaction confidence scores for POFUT1; ( B ) Venn diagram illustrating the overlap between POFUT1-interacting proteins and correlating genes among cancer types; ( C ) heatmap depicting expression patterns of two commonly correlated genes (PLAGL2 and KIF3B) POFUT1 across multiple cancer types; ( D , E ) correlation analyses of POFUT1 expressions with KIF3B (R = 0.79) and PLAGL2 (R = 0.74); ( F ) GO enrichment analysis of POFUT1-interacting and binding partners, showing enriched BP, CC, and MF as visualized bubble plots; ( G ) KEGG pathway enrichment analysis presented as a bubble plot illustrating the involvement of POFUT1-associated genes in key signaling pathways; ( H ) Western blot confirmation of POFUT1 protein expression in prostate adenocarcinoma (RWPE-1, PC-3) and ovarian carcinoma (SKOV3, A2780, IOSE80) cell lines, as well as showing POFUT1 (~44 kDa) and GAPDH (~36 kDa); and ( I ) densitometric quantification of POFUT1 protein expression normalized to GAPDH. Data are presented as mean ± SD from two independent biological replicates. * p < 0.05; **** p < 0.0001. The uncropped blots are shown in .

Article Snippet: PC3, RWPE-1, and SKOV3 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and A2780 was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany), along with normal ovarian surface epithelial cells (IOSE80) as a non-malignant comparator, were selected based on consistent POFUT1 upregulation across TCGA and CPTAC datasets.

Techniques: Functional Assay, Derivative Assay, Expressing, Binding Assay, Protein-Protein interactions, Western Blot

Journal: Scientific Reports

Article Title: Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel

doi: 10.1038/s41598-026-47843-6

Figure Lengend Snippet: Higher expression of CDK9 was present in the resistant ovarian cancer cell line compared to the parental sensitive cell line. ( A ) Relative cell viability of SKOV3 and SKOV3TR cells after incubation with different concentration of paclitaxel for five days. ( B ) Relative cell viability of OVCAR8 and OVCAR8TR cells after incubation with different concentration of paclitaxel for five days. ( C ) Expression levels of CDK9 and related signaling pathway proteins involved in transcription in SKOV3TR and OVCAR8TR, and parental sensitive cell lines SKOV3 and OVCAR8 were determined by Western blot. There are 2 isoforms of the CDK9 protein: the 42 kDa CDK9 isoform and the 55 kDa isoform. The smaller 42 kDa isoform was the first identified isoform. The larger, 55 kDa isoform has a characteristic 117 residue terminal expansion. ( D ) Relative expression of both CDK9 isoforms and α-Tubulin in the ovarian cancer cell lines. ** P < 0.01.

Article Snippet: The human ovarian cancer cell line SKOV3 was purchased from the American Type Culture Collection (Rockville, MD) in 2014 with certificate of analysis.

Techniques: Expressing, Incubation, Concentration Assay, Western Blot, Residue

Journal: Scientific Reports

Article Title: Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel

doi: 10.1038/s41598-026-47843-6

Figure Lengend Snippet: Effects of combination treatment with paclitaxel and CDK9 inhibitor LDC067 on the viability of multidrug resistant ovarian cancer cell line. ( A ) Relative cell viability of SKOV3 and SKOV3TR cells after incubation with different concentration of CDK9 inhibitor LDC067 for five days. ( B ) Relative cell viability of OVCAR8 and OVCAR8TR cells after incubation with different concentration of CDK9 inhibitor LDC067 for five days. ( C and D ) Relative cell viability of SKOV3TR and OVCAR8TR cells in combination with paclitaxel and CDK9 inhibitor LDC067 for five days. N.S. indicates that the observed data for paclitaxel and LDC067 alone treated groups are not statistically significant as compared with untreated groups; * P < 0.05, the observed data for paclitaxel and LDC067 combinatorial treated groups are statistically significant as compared with the untreated groups; ** P < 0.01, the observed results for paclitaxel and LDC067 combinatorial treated groups are highly statistically significant as compared with the untreated groups.

Article Snippet: The human ovarian cancer cell line SKOV3 was purchased from the American Type Culture Collection (Rockville, MD) in 2014 with certificate of analysis.

Techniques: Incubation, Concentration Assay